JP2024533332A5 - - Google Patents
Info
- Publication number
- JP2024533332A5 JP2024533332A5 JP2024515131A JP2024515131A JP2024533332A5 JP 2024533332 A5 JP2024533332 A5 JP 2024533332A5 JP 2024515131 A JP2024515131 A JP 2024515131A JP 2024515131 A JP2024515131 A JP 2024515131A JP 2024533332 A5 JP2024533332 A5 JP 2024533332A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- delivery system
- drug delivery
- based drug
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241705P | 2021-09-08 | 2021-09-08 | |
| US63/241,705 | 2021-09-08 | ||
| PCT/US2022/042701 WO2023038933A1 (en) | 2021-09-08 | 2022-09-07 | Oral abiraterone formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533332A JP2024533332A (ja) | 2024-09-12 |
| JP2024533332A5 true JP2024533332A5 (enExample) | 2025-09-12 |
Family
ID=83508439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515131A Pending JP2024533332A (ja) | 2021-09-08 | 2022-09-07 | 経口アビラテロン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250025417A1 (enExample) |
| EP (1) | EP4398873A1 (enExample) |
| JP (1) | JP2024533332A (enExample) |
| CN (1) | CN118215466A (enExample) |
| WO (1) | WO2023038933A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7644713B2 (ja) | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| JP7850366B2 (ja) * | 2020-09-02 | 2026-04-23 | アステラス ユーエス エルエルシー | アビラテロンプロドラッグ |
| CA3207282A1 (en) * | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| KR20240167653A (ko) * | 2022-03-01 | 2024-11-27 | 프로펠라 쎄라퓨틱스, 인크. | 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도 |
| WO2024107928A1 (en) * | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| US20150337003A1 (en) * | 2013-01-18 | 2015-11-26 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| CN118684633A (zh) | 2018-10-18 | 2024-09-24 | 埃萨制药股份有限公司 | 雄激素受体调节剂及其使用方法 |
| CN113473974A (zh) * | 2019-01-25 | 2021-10-01 | 深圳市药欣生物科技有限公司 | 药物组合物 |
| JP7644713B2 (ja) * | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| EP3944860A1 (en) * | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
| CN113929727A (zh) * | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| CA3207282A1 (en) * | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
-
2022
- 2022-09-07 CN CN202280074455.0A patent/CN118215466A/zh active Pending
- 2022-09-07 JP JP2024515131A patent/JP2024533332A/ja active Pending
- 2022-09-07 EP EP22783117.9A patent/EP4398873A1/en active Pending
- 2022-09-07 WO PCT/US2022/042701 patent/WO2023038933A1/en not_active Ceased
- 2022-09-07 US US18/689,500 patent/US20250025417A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539371A5 (enExample) | ||
| ES2794498T3 (es) | Modulador de receptor de andrógeno en combinación con acetato de abiraterona y prednisona para tratar el cáncer de próstata | |
| AU2011232862B2 (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents | |
| JP7141408B2 (ja) | 前立腺癌の併用療法 | |
| US10220047B2 (en) | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor | |
| Loriot et al. | Recent developments in treatments targeting castration-resistant prostate cancer bone metastases | |
| US20200253988A1 (en) | Adjunctive therapy with 25-hydroxyvitamin d | |
| JP2024506382A5 (enExample) | ||
| De Maeseneer et al. | Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations | |
| Patel et al. | Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors | |
| CN113747882A (zh) | 甲基纳曲酮的液体口服剂量制剂 | |
| JP7309883B2 (ja) | グルココルチコイド受容体モジュレーターの投与によるクッシング症候群における凝固亢進症の治療 | |
| CN111920767B (zh) | 达比加群酯的自微乳组合物、胶囊剂及其制备方法 | |
| US12350276B2 (en) | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| JP2025508944A5 (enExample) | ||
| RU2024129008A (ru) | Пролекарства абиратерона деканоата и их применение в терапии | |
| Melamed | Current concepts in the treatment of prostate cancer | |
| Magné et al. | Florilège des actualités oncologiques internationales en 2019 | |
| Stankovic | Efficacy and safety of docetaxel as first line therapy in high-risk hormone sensitive metastatic pros-tate cancer patients | |
| CN117298062A (zh) | Parp抑制药胶囊及其制备方法 | |
| BR122022022077B1 (pt) | Combinação e composição compreendendo niraparibe, acetato de abiraterona, e prednisona, seu uso para tratar câncer de próstata e kit | |
| HK1217636B (en) | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer | |
| Taylor et al. | Metastatic Castrate-resistant Prostate Cancer: When and How to Treat? |